← Leaderboards
Shijun Zhang
Virginia Commonwealth University
$10,233,701
Attributed
$11,684,836
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,684,836 · 4
By mechanism
U01$5,966,043 · 1
R01$3,828,820 · 2
RF1$1,889,973 · 1
Top collaborators
- Xiang-Yang Wang4 shared
- Dong Sun3 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Mitzi Nagarkatti$16,087,844
- Jenny L. Wiley$18,479,501
- Prakash S. Nagarkatti$24,802,981
- Beatrix Magdalena Ueberheide$5,559,560
- Yan Zhang$14,997,952
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposIn VivoMouse ModelLeadSmall MoleculeS DiseasePropertyStructure-Activity RelationshipDesignIn VitroNeuroinflammationPathogenesisNeurodegenerative DisordersPublic HealthToxic EffectReceptorInflammatory ResponseInflammatoryMarenostrinScaffoldClinical TrialsProductionAnalogInflammasome
Grant awards (15)
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease$1,482,927
U01 · FY2025 · AG · contact PI
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease$1,403,321
U01 · FY2024 · AG · contact PI
Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracers$1,889,973
RF1 · FY2023 · AG · contact PI
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease$1,403,321
U01 · FY2023 · AG · contact PI
Development of NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease$249,901
U01 · FY2023 · AG · contact PI
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease$1,426,573
U01 · FY2022 · AG · contact PI
Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease$610,312
R01 · FY2020 · AG · contact PI
Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease$462,952
R01 · FY2020 · AG · contact PI
Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease$609,829
R01 · FY2019 · AG · contact PI
Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease$609,347
R01 · FY2018 · AG · contact PI
Novel bivalent multifunctional ligands towards Alzheimer's disease$311,703
R01 · FY2016 · AG · contact PI
Novel bivalent multifunctional ligands towards Alzheimer's disease$302,351
R01 · FY2015 · AG · contact PI
Novel bivalent multifunctional ligands towards Alzheimer's disease$311,703
R01 · FY2014 · AG · contact PI
Novel bivalent multifunctional ligands towards Alzheimer's disease$304,148
R01 · FY2013 · AG · contact PI
Novel bivalent multifunctional ligands towards Alzheimer's disease$306,475
R01 · FY2012 · AG · contact PI